Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.75 Million USD | -48.11% |
| 2022 | 3.39 Million USD | -26.85% |
| 2021 | 4.63 Million USD | -5.99% |
| 2020 | 4.93 Million USD | -20.01% |
| 2019 | 6.16 Million USD | -23.2% |
| 2018 | 8.02 Million USD | -41.49% |
| 2017 | 13.72 Million USD | -44.02% |
| 2016 | 24.51 Million USD | -0.57% |
| 2015 | 24.65 Million USD | 46.65% |
| 2014 | 16.81 Million USD | 29.04% |
| 2013 | 13.02 Million USD | -9.13% |
| 2012 | 14.33 Million USD | -33.13% |
| 2011 | 21.44 Million USD | 3.61% |
| 2010 | 20.69 Million USD | 67.88% |
| 2009 | 12.32 Million USD | 19.17% |
| 2008 | 10.34 Million USD | 0.3% |
| 2007 | 10.31 Million USD | 42.79% |
| 2006 | 7.22 Million USD | 26.37% |
| 2005 | 5.71 Million USD | 56.41% |
| 2004 | 3.65 Million USD | 5.75% |
| 2003 | 3.45 Million USD | -51.39% |
| 2002 | 7.1 Million USD | 5367.62% |
| 2001 | 129.99 Thousand USD | 1030.38% |
| 2000 | 11.5 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 911.31 Thousand USD | 56.95% |
| 2024 Q1 | 506.43 Thousand USD | -30.01% |
| 2023 Q4 | 723.56 Thousand USD | -7.69% |
| 2023 Q2 | 784.23 Thousand USD | 0.26% |
| 2023 Q1 | 782.21 Thousand USD | 14.33% |
| 2023 FY | 3.47 Million USD | 2.44% |
| 2023 Q3 | 783.88 Thousand USD | -0.05% |
| 2022 Q1 | 1 Million USD | -18.15% |
| 2022 Q4 | 684.18 Thousand USD | 2.6% |
| 2022 Q3 | 666.82 Thousand USD | -35.87% |
| 2022 FY | 3.39 Million USD | -26.85% |
| 2022 Q2 | 1.03 Million USD | 3.9% |
| 2021 Q4 | 1.22 Million USD | 16.69% |
| 2021 Q2 | 1.18 Million USD | 0.57% |
| 2021 FY | 4.63 Million USD | -5.99% |
| 2021 Q3 | 1.04 Million USD | -11.68% |
| 2021 Q1 | 1.17 Million USD | -1.87% |
| 2020 Q1 | 1.42 Million USD | 21.55% |
| 2020 Q2 | 1.2 Million USD | -15.0% |
| 2020 Q4 | 1.2 Million USD | 9.1% |
| 2020 FY | 4.93 Million USD | -20.01% |
| 2020 Q3 | 1.1 Million USD | -8.77% |
| 2019 Q1 | 1.71 Million USD | -10.74% |
| 2019 Q2 | 1.84 Million USD | 7.47% |
| 2019 Q3 | 1.44 Million USD | -21.56% |
| 2019 Q4 | 1.16 Million USD | -19.03% |
| 2019 FY | 6.16 Million USD | -23.2% |
| 2018 Q2 | 2.28 Million USD | -21.3% |
| 2018 FY | 8.02 Million USD | -41.49% |
| 2018 Q4 | 1.91 Million USD | 41.31% |
| 2018 Q1 | 2.9 Million USD | 0.15% |
| 2018 Q3 | 1.35 Million USD | -40.63% |
| 2017 Q3 | 3.11 Million USD | -5.57% |
| 2017 Q4 | 2.9 Million USD | -6.98% |
| 2017 Q1 | 4.39 Million USD | -15.14% |
| 2017 FY | 13.72 Million USD | -44.02% |
| 2017 Q2 | 3.3 Million USD | -24.9% |
| 2016 Q2 | 5.04 Million USD | -40.7% |
| 2016 Q1 | 8.5 Million USD | -11.96% |
| 2016 Q3 | 5.77 Million USD | 14.51% |
| 2016 Q4 | 5.18 Million USD | -10.28% |
| 2016 FY | 24.51 Million USD | -0.57% |
| 2015 Q3 | 5.77 Million USD | 25.85% |
| 2015 Q1 | 4.62 Million USD | 3.97% |
| 2015 FY | 24.65 Million USD | 46.65% |
| 2015 Q2 | 4.59 Million USD | -0.62% |
| 2015 Q4 | 9.66 Million USD | 67.22% |
| 2014 FY | 16.81 Million USD | 29.04% |
| 2014 Q4 | 4.44 Million USD | 16.17% |
| 2014 Q1 | 4.38 Million USD | 54.05% |
| 2014 Q2 | 4.15 Million USD | -5.06% |
| 2014 Q3 | 3.82 Million USD | -8.03% |
| 2013 FY | 13.02 Million USD | -9.13% |
| 2013 Q4 | 2.84 Million USD | -22.08% |
| 2013 Q3 | 3.65 Million USD | 11.05% |
| 2013 Q2 | 3.28 Million USD | 1.24% |
| 2013 Q1 | 3.24 Million USD | 44.1% |
| 2012 Q2 | 4.28 Million USD | 1.91% |
| 2012 FY | 14.33 Million USD | -33.13% |
| 2012 Q1 | 4.2 Million USD | -4.38% |
| 2012 Q4 | 2.25 Million USD | -37.31% |
| 2012 Q3 | 3.59 Million USD | -16.12% |
| 2011 Q4 | 4.39 Million USD | -41.14% |
| 2011 Q1 | 4.19 Million USD | -13.77% |
| 2011 FY | 21.44 Million USD | 3.61% |
| 2011 Q2 | 5.37 Million USD | 28.27% |
| 2011 Q3 | 7.47 Million USD | 38.89% |
| 2010 FY | 20.69 Million USD | 67.88% |
| 2010 Q4 | 4.86 Million USD | -34.63% |
| 2010 Q3 | 7.43 Million USD | 34.73% |
| 2010 Q2 | 5.52 Million USD | 92.53% |
| 2010 Q1 | 2.86 Million USD | -7.89% |
| 2009 Q4 | 3.11 Million USD | 10.3% |
| 2009 FY | 12.32 Million USD | 19.17% |
| 2009 Q1 | 2.38 Million USD | -15.08% |
| 2009 Q2 | 4 Million USD | 68.09% |
| 2009 Q3 | 2.82 Million USD | -29.52% |
| 2008 Q3 | 2.42 Million USD | -10.63% |
| 2008 Q4 | 2.8 Million USD | 15.66% |
| 2008 FY | 10.34 Million USD | 0.3% |
| 2008 Q1 | 2.39 Million USD | -10.25% |
| 2008 Q2 | 2.71 Million USD | 13.31% |
| 2007 FY | 10.31 Million USD | 42.79% |
| 2007 Q1 | 2.46 Million USD | 20.95% |
| 2007 Q2 | 2.39 Million USD | -2.86% |
| 2007 Q3 | 2.78 Million USD | 16.58% |
| 2007 Q4 | 2.66 Million USD | -4.27% |
| 2006 Q4 | 2.03 Million USD | -0.13% |
| 2006 FY | 7.22 Million USD | 26.37% |
| 2006 Q1 | 1.32 Million USD | -23.53% |
| 2006 Q2 | 1.82 Million USD | 38.33% |
| 2006 Q3 | 2.03 Million USD | 11.57% |
| 2005 Q3 | 1.21 Million USD | -30.04% |
| 2005 FY | 5.71 Million USD | 56.41% |
| 2005 Q4 | 1.72 Million USD | 42.52% |
| 2005 Q1 | 1.04 Million USD | 6.1% |
| 2005 Q2 | 1.73 Million USD | 65.99% |
| 2004 Q1 | 958.59 Thousand USD | 28.72% |
| 2004 FY | 3.65 Million USD | 5.75% |
| 2004 Q4 | 983.55 Thousand USD | -9.29% |
| 2004 Q3 | 1.08 Million USD | 25.25% |
| 2004 Q2 | 865.68 Thousand USD | -9.69% |
| 2003 Q1 | 954.66 Thousand USD | -86.32% |
| 2003 FY | 3.45 Million USD | -51.39% |
| 2003 Q3 | 952.74 Thousand USD | 18.66% |
| 2003 Q4 | 744.72 Thousand USD | -21.83% |
| 2003 Q2 | 802.89 Thousand USD | -15.9% |
| 2002 Q1 | 6594.00 USD | -94.34% |
| 2002 Q4 | 6.97 Million USD | 13242.26% |
| 2002 Q3 | 52.29 Thousand USD | 21.0% |
| 2002 Q2 | 43.21 Thousand USD | 555.43% |
| 2002 FY | 7.1 Million USD | 5367.62% |
| 2001 Q1 | 10 Thousand USD | 150.0% |
| 2001 Q3 | 3401.00 USD | 0.0% |
| 2001 Q2 | - USD | -100.0% |
| 2001 FY | 129.99 Thousand USD | 1030.38% |
| 2001 Q4 | 116.59 Thousand USD | 3328.2% |
| 2000 FY | 11.5 Thousand USD | 0.0% |
| 2000 Q2 | - USD | -100.0% |
| 2000 Q1 | 31.5 Thousand USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | -20 Thousand USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -31.769% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 65.1% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.046% |
| Nascent Biotech, Inc. | 2.22 Million USD | 21.086% |
| Rebus Holdings, Inc. | 664 Thousand USD | -165.012% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.277% |
| Qrons Inc. | 643.67 Thousand USD | -173.379% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -351.702% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.936% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -323.53% |
| Skye Bioscience, Inc. | 13.54 Million USD | 87.011% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.972% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 64.219% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -572.336% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.945% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 39.659% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -17.164% |
| Mesoblast Limited | 5.9 Million USD | 70.185% |
| Marizyme, Inc. | 19.23 Million USD | 90.854% |
| Genus plc | 147.7 Million USD | 98.809% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 79.956% |
| Pharming Group N.V. | 225.49 Million USD | 99.22% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 14.108% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -31.168% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 78.898% |
| ContraFect Corporation | 56.88 Million USD | 96.907% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 60.086% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -18.998% |
| IMV Inc. | 37.7 Million USD | 95.334% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 36.937% |
| MultiCell Technologies, Inc. | 567.42 USD | -310019.136% |
| ONE Bio Corp. | 6.44 Million USD | 72.692% |
| Accustem Sciences Inc. | 3.74 Million USD | 53.03% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.953% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -230.79% |
| Q BioMed Inc. | 3.43 Million USD | 48.796% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 92.88% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 33.029% |
| Biomind Labs Inc. | 994.18 Thousand USD | -76.998% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.228% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 73.807% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 5.615% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 7138.712% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 89.009% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 4.11% |
| GB Sciences, Inc. | 1.42 Million USD | -23.877% |
| Alpha Cognition Inc. | 9.7 Million USD | 81.869% |
| HST Global, Inc. | 140.9 Thousand USD | -1148.822% |
| CSL Limited | 3.44 Billion USD | 99.949% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -56.428% |
| Halberd Corporation | 74.84 Thousand USD | -2251.191% |
| Enzolytics Inc. | 2.17 Million USD | 19.263% |
| Agentix Corp. | 1.37 Million USD | -28.279% |
| Resverlogix Corp. | 12.71 Million USD | 86.157% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 51.799% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.885% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -68.552% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 26.831% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -11.418% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 48.32% |
| AVAX Technologies, Inc. | 7.31 Million USD | 75.929% |
| Zenith Capital Corp. | 8.94 Million USD | 80.323% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.787% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -10000.901% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 28.332% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -925.997% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 8.393% |
| Kadimastem Ltd | 2.41 Million USD | 26.988% |
| Helix BioMedix, Inc. | 1.97 Million USD | 10.768% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 83.807% |
| BioStem Technologies, Inc. | 22.97 Million USD | 92.341% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -869.6% |
| LadRx Corporation | 3.81 Million USD | 53.836% |
| Cell Source, Inc. | 4.32 Million USD | 59.317% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -90.542% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -90.542% |
| NovAccess Global Inc. | 2.46 Million USD | 28.664% |
| Affymax, Inc. | 39.38 Million USD | 95.532% |
| Itoco Inc. | 919.14 Thousand USD | -91.448% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 58.483% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -57.255% |
| Mobile Lads Corp. | 554.54 Thousand USD | -217.319% |
| CytoDyn Inc. | 18.05 Million USD | 90.255% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6891.45% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -699.57% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -23.939% |
| SYBLEU INC | 160.87 Thousand USD | -993.81% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 3.119% |
| International Stem Cell Corporation | 5.27 Million USD | 66.616% |
| Bioxytran, Inc. | 3.82 Million USD | 53.937% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3242.726% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -8550.042% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.148% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -8.756% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -139.14% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 43.437% |
| Neutra Corp. | 243.82 Thousand USD | -621.709% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 89.92% |
| PureTech Health plc | 144.59 Million USD | 98.783% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 91.412% |
| IXICO plc | 4.7 Million USD | 62.616% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 79.997% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.506% |
| CSL Limited | 3.89 Billion USD | 99.955% |
| Cellectis S.A. | 97.32 Million USD | 98.192% |